The cryogenic medical team of our hospital won the 25th invention patent.
Recently, the cryogenic Medical Center of Shandong Yinfeng Life Science Research Institute (the research unit of our foundation) once again obtained the invention patent of "a kind of placental tissue matrix material and its preparation method". Up to now, the total number of patents granted by the cryogenic medical team in the State intellectual property Office has reached 25.
The patent was formally submitted on November 25, 2019, and it took two years to obtain the patent certificate. The patent discloses a placental tissue matrix material, which is a special scaffold material prepared from placental tissue and containing active cytokine receptors, which can actively attract living active components to the material and accumulate cellular active components. support cell attachment, infiltration, growth, proliferation and differentiation.
For a long time, the repair and reconstruction of tissues and organs has always been a research hotspot in the field of tissue engineering, biology and medicine. with the development of technology, tissue engineering products have gradually become an important surgical repair and substitute in clinic. at present, it has become an important treatment for the loss of human tissues and organs and various injuries caused by clinical surgical treatment and accidents. Tissue engineering material is the basis of the research and development of this product, and is expected to become the first choice for surgical repair and substitute in clinic.
At present, most of the tissue engineering materials are mainly composed of natural polymer materials which can provide bioactive components, such as collagen, gelatin, hyaluronic acid, chitosan and so on. however, these traditional tissue engineering materials have some shortcomings, such as insufficient biomechanical strength, poor integration with body tissue, mismatch between degradation rate and tissue reconstruction and so on. Therefore, the use of acellular technology to remove immune cells and DNA in tissue to obtain extracellular matrix (extracellular matrix, ECM) as biomaterials in tissue engineering research stands out.
However, although some domestic acellular tissue matrix (acellular tissue matrix, ACTM) materials have entered preclinical trials, most of them are derived from animal collagen such as pigs and cattle, which is not only expensive and limited in clinical use, but also has the potential risk of infection and immune rejection. Due to the diversification of surgical and clinical needs, tissue engineering products with different specifications, different scales and a variety of structural and activity requirements are needed. Conventional extracellular matrix and scaffolds are difficult to meet.
For this reason, the Yinfeng Cryogenic Center provides a kind of medical biomaterial, placental tissue matrix material, which is prepared from human placental tissue. The placental tissue matrix material of the invention does not contain immune antigens of allogenic tissues, retains the receptors of a variety of active factors in the placental tissue extracellular matrix, and has various forms (such as particles, gels and porous scaffolds). The placental tissue matrix material of the invention can be implanted into tissue defects and wounds in the body, contribute to the accumulation of cell active components, support cell migration, attachment, proliferation and differentiation, accelerate the repair of injured tissue, and meet the clinical needs of different parts and shapes.
Yinfeng Cryogenic Medical Center will speed up technological innovation, promote the transformation of achievements, and promote the early application of the acellular matrix obtained by the invention in the fields of burn plastic surgery, medical cosmetology, diabetic foot and so on. It has become an important surgical repair and substitute for clinical treatment and life-saving, and serves for human health.